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ApoptosisThe Epstein–Barr virus (EBV) infects and transforms primary B cells into lymphoblastoid cell lines (LCLs). We
observed death-associated protein kinase 1 (DAPK1) upregulation in B cells following EBV infection and high
DAPK1 levels in LCLs. DAPK1 participates in several apoptosis-inducing pathways, yet DAPK1 expression
increased during B cell transformation. Data from LMP1 overexpression in LCLs and HeLa cells and from
knocked down LMP1 in LCLs suggest LMP1 regulation of DAPK1 expression. We observed NF-κB signaling in
DAPK1 upregulation by LMP1with CTAR deletionmutants failing to induce DAPK1 expression andwith Bay11
blocking DAPK1 expression. DAPK1 is inactive in LCLs due to insufﬁcient stimuli, and is not regulated by
Ser308 phosphorylation. However, DAPK1 in LCLs is functional, as evidenced by its quick mediation of cell
death following UV or H2O2 exposure, and increased survival among LCLs knocked down with DAPK. DAPK
roles in EBV-infected B cells remain to be identiﬁed.logy and Laboratory Science in
c. 2, Li-Nong St., Taipei 112,
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The Epstein–Barr virus (EBV) is capable of establishing life-long
infections andmaintaining latency in over 95% of immuno-competent
adults (Babcock et al., 1998; Henle et al., 1969). In vitro, EBV
immortalizes B cells into lymphoblastoid cell lines (LCLs), causing
them to harbor episomal genomes and persistent infections (Kieff,
1996). Viral proteins expressed in LCLs include latent membrane
proteins (LMPs) 1, 2A, and 2B, and Epstein–Barr nuclear antigens
(EBNAs) 1 through 6, each with a distinct function (Kieff, 1996).
EBNA1 maintains the episomal genome(Kieff, 1996), and EBNA2
(involved in immortalization) acts as a Notch receptor activating
RBP-Jκ repressed promoters (Grossman et al., 1994; Henkel et al.,
1994). LMP1, a major transforming protein, mimics a constitutively
activated CD40-TNF (tumor necrosis factor) receptor (Eliopoulos and
Young, 2001; Uchida et al., 1999). LMP1 controls both cell prolifer-
ation and death by exploiting the features of TNF receptors, which are
considered crucial to cell growth, differentiation, and apoptosis (Gaurand Aggarwal, 2003; Pimentel-Muinos and Seed, 1999; Soni et al.,
2007).
In vivo, EBV maintains latency to avoid immune system detection.
A sudden change in equilibrium between immune control and virus–
cell interaction can lead to the insufﬁcient killing or overproliferation
of virus-infected cells, resulting in lymphoproliferative syndrome in
immunocompromised patients, Burkitt's lymphoma, or Hodgkin's
disease (Middeldorp et al., 2003). LMP1 promotes cell proliferation
and inhibits apoptosis—both important for immortalization (Kaye
et al., 1993; Li and Chang, 2003). However, LMP1 is also capable of
upregulating Fas and sensitizing cells to become pro-apoptotic
(Dirmeier et al., 2005). These contradictory functions maintain
EBV-infected cell homeostasis.
Death-associated protein kinase 1 (DAPK1) is a Ca2+/calmodulin-
dependent Ser/Thr kinase requiring regulation due to its status as a
pro-apoptotic protein (Cohen et al., 1997). DAPK1 action is necessary to
induce cell death via such stimuli as death receptors, cytokines,
extracellular matrix detachment, or hyperproliferation due to oncogene
activation (Cohen et al., 1999; Inbal et al., 1997; Jang et al., 2002; Pelled
et al., 2002; Raveh et al., 2000). Due to its autoinhibitory mechanism,
DAPK1 activation requires the dephosphorylation of Ser308 and Ca2+/
calmodulin binding (Shohat et al., 2001). Extracellular signal-regulated
kinase (ERK) and mitogen activated protein kinase (MAPK) signaling
20 C.-W. Lee et al. / Virology 413 (2011) 19–25pathways are also involved in DAPK1 action regulation (Anjum
et al., 2005; Chen et al., 2005). Furthermore, respective Tyr491/492
phosphorylation or dephosphorylation by Src or leukocyte common
antigen-related tyrosine phosphatase (LAR) reciprocally modulates
DAPK1 function (Wang et al., 2007).
In this study, we identiﬁed a cellular protein DAPK1 which is
upregulated in EBV-infected B cells and LCLs. Since DAPK1 is pro-
apoptotic, we further investigated its regulation in B cells. The tight
regulation on DAPK1 activation ensures cell survival and may play a
role in maintenance of EBV latency in B cells.
Results and discussion
To study EBV gene expression proﬁle in LCLs, we puriﬁed primary
CD19+ B cells using magnetic bead separation from leukocyte
concentrates and infected them with the B95-8 EBV virus. Total RNA
was extracted from cells harvested 0, 7, 14, and 28 days post-infection
and used for microarray analyses; DAPK1 was among the highly
induced genes we observed. Real-time PCR and immunoblotting
analysis were used to conﬁrmmicroarray results. As shown in Fig. 1A,
gradual increases in DAPK1 expression were detected on days 3, 7, 14,
21 and 28, and high DAPK1 levels were maintained in lymphoblastoid
cell lines following normalization to DAPK1 levels in uninfected B cells
(day 0) (Fig. 1B). Very little change in DAPK1 expression was noted in
B cells that were either cultured for 2 days without infection or
stimulated with PMA. Similar protein upregulation data were
produced by immunoblotting. EBV infection was conﬁrmed by
EBNA1 expression (Fig. 1C).
As one EBV latent protein, LMP1 affects broad cellular gene
expression, especially among cell growth genes (Dirmeier et al.,
2005). Because hypermethylation exists in the DAPK1 promoterFig. 1. Increased DAPK expression in EBV-infected B cells. (A) Puriﬁed B cells were infected
DAPK expression was analyzed by real-time PCR. B cells cultured for 2 days without infectio
2 days (PMA) are shown. Relative DAPK expression was normalized to day 0 B cells. Increa
levels in ﬁve LCL lines. (C) Total cell lysates were prepared at different time points; total
anti-DAPK and anti-EBNA1 antibodies (CHK2 as internal control).region in most B cell lines, we used epithelial cell lines to investigate
links between LMP1 and DAPK1. We transfected LMP1 plasmid in
HeLa cells and used a combination of RT-PCR and immunoblotting to
analyze DAPK1 expression. As shown in Fig. 2A, DAPK1 was
upregulated following LMP1 overexpression. LMP1 transient trans-
fection in two LCL cell lines also resulted in DAPK1 upregulation
(Fig. 2B). In contrast, reduced LMP1 expression by siRNA knockdown
decreased DAPK1 expression (Fig. 2C). Since carboxy-terminal
activating regions 1 and 2 (CTAR1 and CTAR2) are responsible for
LMP1 signaling (Huen et al., 1995), we looked at the potential effects
of CTAR-deleted LMP1 mutants on DAPK1 expression. DAPK1
expression was not increased after HeLa cells were transfected
with various CTAR mutants, especially the CTAR2 deletion and double
CTAR deletion mutants (Fig. 2D). This suggests that CTAR2 has
greater importance in terms of LMP1 signaling in DAPK1 expression
regulation.
We used several inhibitors to determine the downstream signaling
pathway responsible for DAPK1 induction by LMP1. LCLs showed
decreased DAPK1 levels following treatment with Bay11, which
speciﬁcally inhibits the NF-κB pathway (Fig. 3A). The addition of
35 μM of Bay11 reduced DAPK1 levels in LMP1-expressing HeLa cells;
higher concentrations of Bay11 signiﬁcantly decreased DAPK1 expres-
sion (Fig. 3B). According to theseﬁndings, DAPK1 is positively regulated
by the NF-κB pathway. To identify other signal transduction pathways
for DAPK1 induction, we tested the MAPK inhibitors SP600125,
SB203580, and PD98059. Even though these inhibitors respectively
block JNK, p38, and ERK phosphorylation, in this experiment they failed
to downregulateDAPK1 expression in LCLs (Fig. 3C). Combinedwith the
CTAR deletion LMP1 mutant data, these results indicate that NF-κB is
capable of mediating DAPK1 induction by LMP1 in both LCLs and HeLa
cells, but MAPK signaling pathways are not.with B95.8 strain EBV and harvested for total RNA extraction at different time points.
n (2D−) and B cells treated with 25 ng/ml PMA (phorbol 12-myristate 13-acetate) for
sed DAPK transcripts are noted in EBV-infected B cells. (B) DAPK transcript expression
proteins (20 μg) were separated by SDS-PAGE and analyzed by immunoblotting with
Fig. 2. EBV viral protein LMP1mediates DAPK expression. (A) HeLa cells (5×105) were transfected with LMP1 expressing vector or pCMV2 for 18 h prior to total RNA extraction. RNA
(2 μg) was used for RT-PCR analysis. Cell lysates were prepared 24 h post-transfection for immunoblotting. (B) LCL01 and LCLS11 cells (2×106 each) were electroporated with 8 μg of
LMP1 expressing vector or pCMV2 control vector. Total RNAwas extracted after 36 h; 2 μgwere used for RT-PCR analysis. DAPK, LMP1 and GAPDH protein levels were determined by
immunoblotting 48 h post-electroporation. (C) LCL cells (1×106) were electroporated with different concentrations of LMP1-siRNA or control GFP-siRNA. LMP1 and DAPK
expression was determined by immunoblotting 48 h post-electroporation. (D) HeLa cells (4×105) were transfected with 4 μg of pCMV2, wild type LMP1 (LMP1 WT), or different
CTAR-deleted mutants. Total proteins were collected at 24 h for DAPK detection by immunoblotting. DAPK and LMP1 intensities were estimated using Quantity One software
(Bio-Rad Laboratories, Hercules, CA) and calculated as relative folds of expression (see histogram). Data are presented as mean±SD (*pb0.05, two-tail Student's t-test).
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we speculated that DAPK1 is inactive in LCLs. To test this idea
we performed in vitro kinase assays to evaluate DAPK1 activity. As
shown in Fig. 4A, Flag-DAPK1 overexpression and immunoprecipitation
inHEK293T cells resulted in the phosphorylation ofmyosin light chains;
no kinase activity was detected in endogenous DAPK1 immunopreci-
pitated with anti-DAPK1 antibodies in LCLs. Ser308 (S308) phosphor-
ylation has been shown to inhibit DAPK1 catalytic activity (Shohat et al.,
2001); however, in this study the S308 phosphorylation of DAPK1 in
LCLs was barely detectable (Fig. 4B). This suggests that S308
phosphorylation does not account for the lack of DAPK1 activity in
LCLs, therefore other regulatory mechanisms are likely involved.
Since DAPK1 is inactive, we tried to determine if it loses its
biological function in LCLs. We used shRNA to knock down DAPK1expression in LCLs, followed by PI (propidium iodide) staining and cell
proliferation WST1 assays for evaluating cell viability in response to
death signals following treatment with ultraviolet (UV) or H2O2
(Fig. 4C). Post-UV or H2O2 treatment, we observed lower cell death
rates (Supplemental Data) and higher survival rates (Fig. 4D and E) in
shDAPK1 clones (low DAPK1 expression). According to a previous
report, H2O2-activated DAPK1 phosphorylates protein kinase D (PKD)
at Ser910 (S910) and regulates JNK signals leading to cell death
(Eisenberg-Lerner and Kimchi, 2007). We tried to determine if PKD is
phosphorylated by DAPK1 under oxidative stress. As shown in Fig. 4F,
p-PKD expression was detected by immunoblotting, indicating
upstream DAPK enzymatic activity. According to these results,
DAPK1 is functional in LCLs, since it plays a role in cell death
associated with oxidation or irradiation stress.
Fig. 4. DAPK in LCLs is inactive until subjected to stress. (A) Endogenous DAPK activity was determined by in vitro kinase assay. DAPK proteins were precipitated from LCLs and
DAPK-expressing HEK293T cell lysates, and incubated with MLC and γP32-ATP at room temperature for 15 min. Autoradiography was performed to check kinase activity. DAPK
protein levels are also shown. (B) Total proteins fromHEK293 and LCL (20 μg each) were blotted with anti-DAPK and anti-DAPK pS308 antibodies. (C) DAPK expression was knocked
down in shDAPK983 and shDAPK984. shLuc cells served as a negative control. 2×106 cells were stimulated in the presence or absence of UVC exposure (254 nm) (D) or treated with
1 mM H2O2 (E). UV-exposed cells and H2O2-treated cells were collected at 18 h and 24 h, respectively. Cell survival was determined by WST-1 proliferation assay. Survival
percentage was calculated as O.D. 450 absorbance in each batch of treated cells divided by absorbance in untreated cells. Results are expressed as mean±SD (*pb0.05, two-tail
Student's t-test). (F) Endogenous DAPK gains enzymatic activity to phosphorylate downstream PKD substrate in H2O2-treated LCL cells. LCL-shLuc cells (2×106) were left untreated
or treated with 2 mM H2O2 for 24 h. Total proteins (20 μg) were immunoblotted with anti-PKD and anti-PKD pS910 antibodies.
Fig. 3. DAPK expression in LCL is mediated by NF-κB signaling. (A) LCL cells (2×106) were treated with NF-κB inhibitor Bay11-7082 (0, 3 or 5 μM) for 24 h. Total proteins (20 μg)
were separated by SDS-PAGE and immunoblotted with anti-DAPK, anti-LMP1, or anti-GAPDH antibodies. Nuclear protein (40 μg) was immunoblotted with anti-NF-κB p65
antibodies. (B) HeLa cells (4×105) were transfected with pCMV2 or LMP1 vectors and incubated at 37 °C for 24 h followed by treatment with 35 μM or 50 μM of Bay11-7082 or
DMSO as control and cultured for 18 h. Total proteins were collected for immunoblotting. (C) LCL cells (2×106) were treated with different quantities of SP600125 (JUN inhibitor),
SB203580 (p38 inhibitor), or PD98059 (ERK inhibitor) for 24 h. DAPK levels were compared by immunoblotting. Phosphorylated forms of MAPK (p-JNK, p-p38 and p-ERK) were
used to demonstrate the inhibitory effects of MAPK inhibitors; JNK, p38, and ERK served as loading controls.
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vectors, and found that only LMP1 mediates DAPK1 upregulation
(data not shown). LMP1 is the primary viral protein responsible for B
cell transformation and proliferation via NF-κB signaling (Li and
Chang, 2003; Soni et al., 2007). In addition to stimulating cell growth,
LMP1 also upregulates anti-apoptotic molecules such as Bcl-2, A-20,
and Mcl-1 (Fries et al., 1996; Henderson et al., 1991; Laherty et al.,
1992; Wang et al., 1996). However, note that LMP1 is still capable of
(a) upregulating Fas expression in LCLs recognized and killed by FasL
expressing cytotoxic T cells and (b) promoting apoptosis in some cells
(Falk et al., 1992; Larochelle et al., 1998; Le Clorennec et al., 2006).
According to a previous report, LMP1 overexpression in LCLs induces
apoptosis via Fas and caspase 8 (Le Clorennec et al., 2008). The same
researchers suggest that LMP1-dependent NF-κB signaling (which
mediates Fas overexpression) may counteract the anti-apoptotic
effects of NF-κB. Evidence has also been gathered indicating that
NF-κB is a mediator of LMP1-induced cell death (Nitta et al., 2003). It
may be that NF-κB signaling in LCLs results in apoptosis triggered by
pro-apoptotic stimuli beyond the control of anti-apoptotic factors.
There appears to be a correlation between LMP1 effects and
expression level. As demonstrated in epithelial cells (Lu et al., 1996)
and B cell lines (Floettmann et al., 1996), increased LMP1 levels tend
to result in cell growth arrest or apoptosis. LMP1 function (which
promotes cell proliferation at normal levels and induces cell death at
high levels) is similar to that of c-myc. p53 induction is associated
with LMP1 and c-myc overexpression (Le Clorennec et al., 2006). The
contradictory functions of the same protein may act as a switch for
self-protection in the form of preventing the excessive growth of
EBV-infected cells. LMP1 levels are increased by the JNK pathway but
decreased by NF-κB activation (Goormachtigh et al., 2006). It has been
reported that EBV not only immortalizes B cells but also sensitizes
infected B cells for elimination by cytotoxic T cells (Le Clorennec et al.,
2008). Despite the importance of Fas upregulation by LMP1 via NF-κB,
we believe DAPK1 may be another cellular protein target induced by
similar pathways, one playing a role similar to that of Fas. The balance
between cell proliferation and the expression of pro-apoptotic
proteins dependent on LMP1 and NF-κB levels may be the basis for
EBV-immortalized B cell conﬁnement by the immune system.
In most tumors, DAPK1 expression is silenced due to promoter
hypermethylation, yet still expressed in human renal cell carcinomas
(RCC) and acutemyelogenous leukemia (Guzman et al., 2001). Results
from in vitro kinase assays indicate that RCC cell lines overexpress
DAPK1without detectable activity (Wethkamp et al., 2006).We found
that LMP1 activation is capable of inducing the expression of the
pro-apoptotic DAPK1 protein. This protein quickly responds to
oxidative stress or UV stimulation by promoting programmed cell
death. Identifying DAPK1 expression in LCLs is a possible mechanism
for the homeostatic control of in vivo latency.
Conclusions
In summary, our results indicate that DAPK1 is gradually
upregulated in EBV-infected primary B cells and maintains high
expression levels in LCLs. We also found that LMP1 is involved in
DAPK1 induction, and that NF-κB signaling participates in this
upregulation. In addition, we determined that DAPK1 remains
inactive under normal conditions, and is activated by external stimuli
such as UV or oxidative stress.
Materials and methods
Cell culture and EBV infection
EBV B95.8 strain was prepared prior to B cell infection. 40 ng/ml
12-O-tetradecanoylphorbol-13-acetate (TPA)(Sigma-Aldrich, St.
Louis, MO) and 3 mM sodium butyrate (Sigma-Aldrich) were addedto B95.8 cell culture medium and incubated at 37 °C for 72 h. Viral
particles in supernatant were collected by centrifugation and
concentration. After 0.45 μm ﬁltration (Millipore, Billerica, MA),
viruses were aliquoted and stored at −80 °C. Total B cells were
puriﬁed by Ficoll-Paque (GE Life Sciences, Uppsala, Sweden). Human
peripheral blood mononuclear cells (PBMCs) were separated with
EasySep human CD19 selection cocktail (StemCell Technologies,
Vancouver, Canada) following the manufacturer's instructions. Puri-
ﬁed B cells (2×106/well) were infected with B95.8 strain EBV in a
12-well plate. Infected B cells were maintained for at least 28 days to
produce lymphoblastoid cell lines (LCLs). One LCL 01 and one LCL S11
strain were developed from different blood donors. Infected B cells
and LCLs were cultured in RPMI medium (Gibco, Carlsbad, CA)
containing 10% FBS (Gibco) and 1% Pen-Strep antibiotic solution
(Biological Industries, Kibbutz Beit Haemek, Israel). HeLa, HEK293T,
and HEK293 cells were grown in DMEM medium (Gibco) with 10%
FBS (Gibco). NF-κB inhibitor Bay11-7082, JNK inhibitor SP600125,
p-38 inhibitor SB203580, and ERK inhibitor PD98059 were purchased
from Merck (Darmstadt, Germany).
Plasmids and gene transfection
The LMP1 EBV viral protein expression vector and pCMV2 control
vector (both provided by Dr. Y.-S. Chang, Chang Gung University,
Taoyuan, Taiwan) were overexpressed in LCLs and HeLa cells by
electroporation and transfection, respectively. Plasmids (4 μg) were
transfected into adherent HeLa cells with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) following the manufacturer's instructions.
For LCLs, 2×106 cells were electroporated with 8 μg of plasmids using
a MicroPorator (NanoEnTek, Seoul, South Korea) (1375 V, 30 ms, 1
pulse). Plasmids with LMP1 CTAR-deleted mutants were provided by
Dr. C.-J. Chen (National Yang-Ming University, Taipei).
RT-PCR and real-time PCR
Total cellular RNA from LCL andHeLa cells was extractedwith TRIzol
reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized from 2 μg of
total RNA by reverse transcription with a RevertAid First Strand cDNA
Synthesis Kit (Fermentas, Burlington, Canada) according to the
manufacturer's instructions. To detect DAPK expression, PCR was
performed with RT products, primers, dNTP, and Taq polymerase as
follows: 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 1 min (30 cycles
total). Primers for DAPK amplicons (496 bp) were 5'-TGCGGCCAA
CAACGGAATC-3' (forward) and 5'-GGGTCGGGGCCA CAAACAC-3' (re-
verse). GAPDH amplicons (598 bp) were ampliﬁed using the primers
5'-GGGTGTCGCTGTTGAA-3' (forward) and 5'-GCTGAGTACGTCGTGG-3'
(reverse). To analyze DAPK transcripts in EBV-infected B cells with real-
time PCR, RT products weremixedwith Human Universal Probe Library
Taqman probe No. 45 (Roche, Basel, Switzerland), forward primer
5'-TGCTGAAAGAGATTAGGAACAGG-3', reverse primer 5'-CGAAGTAC
CTTCATGTCCTTTGA-3', and FastStart Taqman Probe Master mix
(Roche). Reactions were ampliﬁed with ABI PRISM 7900 as follows: 1
cycle of 50 °C for 2 min and 60 °C for 1 min, followed by 40 cycles of
95 °C for 15 s and 60 °C for 1 min.
Immunoblotting
Total cellular proteins were prepared directly from cell lysates. For
nuclear protein extraction, cells were mixed with buffer I (10 mM
HEPES, 10 mMKCl, 1.5 mMMgCl2), held on ice for 15 min, mixedwith
buffer II (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 2.5% NP-40), and
held on ice for 5 min. After centrifugation, nuclear proteins from cell
pellets were resuspended in buffer III (20 mM HEPES, 0.45 M NaCl,
1.0 mM EDTA), sonicated, and collected by additional centrifugation.
20 μg total proteins or 40 μg puriﬁed nuclear proteins were separated
by SDS-PAGE, transferred to an Immobilon P membrane (Millipore,
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amounts were visualized on X-ray ﬁlm in the presence of Immobilon
Western Chemiluminescent HRP substrate (Millipore, Billerica, MA).
The following antibodies were used in this study: anti-DAPK and
anti-DAPK pS308 (purchased from Sigma-Aldrich); anti-EBNA1 and
CHK2 (provided by Dr. C.-H. Tsai, National Taiwan University); anti-
LMP1 (provided by Dr. C.-J. Chen, National Yang-Ming University);
and anti-GAPDH (purchased from Novus Biologicals, Littleton, CO).
The following antibodies were used for signaling study: JNK, ERK1/2,
and p-ERK1/2 (purchased from Millipore, Billerica, MA); and p-JNK,
p38, and p-p38 (purchased from Santa Cruz Biotechnology, Santa
Cruz, CA). Anti-PKD (Cell Signaling Technology, Danvers, MA) and
anti-PKD pS910 antibodies (Abcam, Cambridge, MA) were used to
analyze DAPK downstream substrate phosphorylation.
Small interfering RNA (siRNA)
Oligonucleotides corresponding to the B95.8 stain of EBV LMP1-
speciﬁc siRNA duplexes were synthesized as sense 5'-GGAAUUUGCACG-
GACAGGCUU-3' and antisense 5'-GCCUGUCCGUGCAAAUUCCUU-3' (2).
Control siRNA was synthesized to target GFP expression. Duplex
sequences were sense 5'-GCACGACUUCUUCAAGUCCUU-3' and antisense
5'-GGACUUGAAGAAGUCGUG CUU-3'. LCL cells (1×106) were electro-
porated with 200 μM LMP1-siRNA or control GFP-siRNA. LMP1 and
DAPK expression were determined by immunoblotting 48 h post-
electroporation.
In vitro kinase assay
Endogenous DAPK proteins were immunoprecipitated and DAPK
activity was measured as degree of phosphorylation on myosin light
chain (MLC) substrate using γP32-ATP. Brieﬂy, proteins from LCLs
were incubated with anti-DAPK antibodies at 4 °C overnight, followed
by absorption with protein A/G beads (Calbiochem, San Diego, CA) for
3 h at 4 °C. After washing with cold NP40 lysis buffer and 1× kinase
buffer (50 mM HEPES, 8 mM MgCl2, 2 mM MnCl2, 0.1 mg/ml bovine
serum albumin), beads were incubated at room temperature for
15 min in 50 μl of prepared reaction buffer containing 1×kinase
buffer, 10 μM bovine CaM, 5 mM CaCl2, 5 μg GST-MLC, 1 mM ATP and
10 μCi γP32-ATP (GE Life Sciences, Uppsala, Sweden). Reactions were
stopped by SDS sample buffer and held at 95 °C for 5 min. Super-
natants were separated with SDS-PAGE and transferred to PVDF
membrane. Autoradiography was performed to determine kinase
activity; the same membrane was blotted with anti-DAPK antibodies.
Positive controls were prepared from the lysates of DAPK-expressing
HEK293T cells (pRK5F-DAPK plasmid and anti-ﬂag antibody precip-
itation) (Sigma-Aldrich, St. Louis, MO).
Lentivirus knockdown system
Lentivirus shRNA clones (pLKO.1-shDAPK983 and pLKO.1-
shDAPK984) and two plasmids (pMD.G and pCMV deltaR8.91) were
provided by the National RNAi Core Facility at Academia Sinica, Taipei.
Corresponding shRNA sequences to DAPK were 5'-CCGGCCACGTCGA-
TACCTTGA AATTCTCGAGAATTTC AAGGTATCGACGTGGTTTTT-3'
(pLKO.1-shDAPK 983) and 5'- CCGGCGGCACCTCTTACAATTCCATCTC-
GAGATGGAATTGTAAGAG GTGCCGTTTTT-3' (pLKO.1-shDAPK 984).
For lentivirus preparation, three constructs were co-transfected into
HEK293T cells. Virus supernatants were collected at 24, 36, and 48 h.
Following 0.22 μm ﬁltration, viruses were aliquoted and stored until
used. To generate DAPK-knockdown LCL cells, equal volumes of LCLs
and lentivirus supernatant were incubated with 8 μg/ml protamine
sulfate (Sigma-Aldrich) at 37 °C for 24 h. DAPK knockdown LCL cells
were selected and maintained in fresh medium containing 2 μg/ml
puromycin (Sigma-Aldrich). shLuc cells (pLKO.1-shLuc, a luciferase
shRNA-expressing plasmid) were used as a negative control.UV irradiation and H2O2 treatment
To test for stress response and DAPK activity, LCL-shLuc, LCL-
shDAPK983, and LCL-shDAPK984 cells were exposed to UV or treated
with oxidativeH2O2. Brieﬂy, 2×106 cellswere stimulated in the presence
or absence of UVC (254 nm) at 2 mJ/cm2 using a UV Stratalinker
(Stratagene, La Jolla, CA), or treated with 1 mM H2O2. UV-exposed cells
were collected at 18 h andH2O2-treated cellswere harvested at 24 h. Cell
survival was determined using WST-1 proliferation reagent (Clontech,
Mountain View, CA) following the manufacturer's instructions. Survival
percentagewas calculatedasO.D. 450absorbance in eachbatchof treated
cells divided by absorbance in untreated cells.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.01.032.
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